Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

IMI-PainCare: Public-private Partnership Tackles Major Challenges in the Care of Pain Patients


News provided by

IMI-PainCare

05 Jun, 2018, 12:00 GMT

Share this article

Share toX

Share this article

Share toX

AACHEN, Germany, June 5, 2018 /PRNewswire/ --

To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project "IMI-PainCare - Improving the care of patients suffering from acute or chronic pain" on April 01, 2018. The consortium strives to develop a toolbox that can streamline the research and development process for novel analgesic drugs and improve treatment quality in clinical practice. The project comprises three sub-projects across all phases of the pharmaceutical value chain - from early research to clinical practice - addressing major challenges in the care of patients suffering from acute or chronic pain in a complementary manner. It is anticipated that tools will be validated that will allow patient stratification and enrichment as recommended by the recent EMA/CHMP/970057/2011 guideline on pain treatment.

IMI-PainCare is set within the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership for health research worldwide. The project is driven by a consortium of 40 partners from 14 countries, while the lead is shared by Rolf-Detlef Treede, University of Heidelberg, and Petra Bloms-Funke, Grünenthal. IMI-PainCare is supported by the IMI 2 Joint Undertaking with € 11.2 million provided by the European Union. The industrial partners will provide € 12.0 million through direct and in-kind contributions, e.g. employees working on the project in partnerships with the consortium. The project runs over four years and will end on March 31, 2022.

Pain management is essential for all medical conditions, as it is one of the major dimensions of Quality-of-life scores that patients report. Additionally, chronic pain may outlast the normal healing process (e.g. after surgery). It can be a symptom of a chronic disease (e.g. endometriosis, bladder pain syndrome, diabetic neuropathy) or may occur without any signs of an underlying disease. The treatment of both acute and chronic pain is often inadequate, which underlines the high need for innovative solutions to improve pain management. This is partly due to a poor translation of results from preclinical models into clinical trials, and partly due to a lack of sophistication in outcome reporting and accurate division of patients into subgroups in clinical trials.

"Acute and persistent pain of different origins represent a common medical, social, and economic burden, and improvement of its management is still a major challenge for all health care systems. I look forward to working towards innovative solutions to these unmet medical needs together with my partners of IMI-PainCare which represents an unprecedented close cooperation between academia, SMEs, patient organizations, pain societies and pharmaceutical companies," Rolf-Detlef Treede, University of Heidelberg, explained. "I am delighted that we were able to bring together the expertise of 40 partners to drive innovative solutions in pain management. The joint work of these best-in-class experts may enable us to provide pain patients with the appropriate prevention or treatment for their condition at the right time", Petra Bloms-Funke, Grünenthal, stated.

"Providing standardized consented patient-reported outcome measures" (PROMPT) is the first sub-project, led by Winfried Meissner, University of Jena, and Hiltrud Liedgens, Grünenthal. It is located in a key area of both clinical research and clinical practice and has the patient's perspective in its focus. "We aim to improve the management of pain by defining a consented set of patient-reported outcome measures which is suitable to assess acute and chronic pain in controlled trials as well as real world conditions. It would be beneficial for patients if success is documented routinely after pain treatment, and the tools we aim to identify can help with this", Winfried Meissner stated. "A defined set of patient-reported outcome measures in clinical trials of novel analgesics could become a discussion basis in our exchange with regulatory authorities, especially when defining claims in submission documents, and with Health Technology Assessment Agencies (HTAs) when we have to discuss relevant clinical benefits to gain reimbursement," Hiltrud Liedgens, Grünenthal, added.

"Functional pain biomarkers" (BioPain) - the second subproject - is led by Rolf-Detlef Treede, University of Heidelberg, and Keith Phillips, Eli Lilly and Company. It is located in the transition stage from pre-clinical to early clinical development and aims to establish pharmacokinetic / pharmacodynamic models in healthy humans and rodents. "Functional electrophysiological and imaging tests validated in experimental pain models could be a basis for the creation of purposeful clinical endpoints, also in patients," Rolf-Detlef Treede, University of Heidelberg explains. "If these clinical markers prove their reliability, we could aim to carry them into preclinical models as well. This could improve our candidate selection and may increase the chance of a successful translation from preclinical to clinical development," Keith Phillips, Eli Lilly and Company, added.

The subproject "Translational research in pelvic pain" (TRiPP) is led by Katy Vincent, University of Oxford, and Jens Nagel, Bayer. It has a special focus on pain related to endometriosis and interstitial cystitis / bladder pain syndrome and is located in clinical practice as well as the early stage of disease understanding to provide a robust pre-clinical environment for drug development. "We aim to determine subgroups within these diseases and identify biomarkers of these clinical phenotypes. Ultimately, we hope this strategy will move towards more personalised treatments for these distressing conditions", Katy Vincent stated. "It is of key importance to understand better the molecular pathways leading to inflammation and chronic pelvic pain both in endometriosis and bladder pain syndrome and to assure that these are reflected in pre-clinical models to improve their translational value for clinical research," Jens Nagel added.

About the Innovative Medicines Initiative 

The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, and other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

More info on IMI: http://www.imi.europa.eu

Follow IMI on Twitter: @IMI_JU

Acknowledgement
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777500. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA Companies.

Disclaimer
This communication reflects the views of the IMI-PainCare consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.

Contact 

Project Office/General Enquires:

Email: info@imi-paincare.eu
Project Leader: Petra Bloms-Funke, Grünenthal GmbH. +49-241-569-2697
Project Coordinator: Rolf-Detlef Treede, Ruprecht-Karls-Universität Heidelberg. +49-621-383-9926.
Project Manager: Daniel Schubart, ConsulTech GmbH. +49-307-720-5920.

Please visit our website for more information on the IMI-PainCare project 

http://www.imi-paincare.eu

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.